ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Solute carrier family 16 member 3 is a target of nodakenetin in breast cancer.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nodakenetin is a plant-derived coumarin with anti-tumor activities. However, the roles of nodakenetin in treating breast cancer are unknown. This study aimed to investigate the effects of nodakenetin on breast cancer cell viability, apoptosis, and glycolysis, and to explore its action mechanisms. MCF-7 and MDA-MB-468 cell Lines were used in this research. Cell viability was detected by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay, and apoptosis was investigated by TdT-mediated dUTP nick-end labeling and flow cytometry assays. Glycolysis was evaluated by determining glucose uptake, lactate production, and adenosine triphosphate (ATP) level. Solute carrier family 16 member 3 (SLC16A3) expression was detected by qRT-PCR and western blotting. The clinical expression of SLC16A3 was analyzed using bioinformatics analysis. We found that nodakenetin reduced the viability and increased apoptosis in breast cancer cells. Nodakenetin suppressed glycolysis in breast cancer cells by decreasing glucose uptake, lactate production, ATP level, and extracellular acidification rate. Moreover, SLC16A3 was identified as a target of nodakenetin and an oncogene in breast cancer. Nodakenetin decreased SLC16A3 expression. SLC16A3 upregulation reversed the effects of nodakenetin on the viability, apoptosis, and glycolysis in breast cancer cells. Additionally, nodakenetin treatment suppressed the growth of breast cancer cells in nude mice. Our findings suggest that nodakenetin inhibits the viability, promotes apoptosis, and represses glycolysis in breast cancer cells through decreasing SLC16A3 expression, proving the anti-cancer potential of nodakenetin in breast cancer.
Indexed as
Identifiers
40911046What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.